INTRODUCTION
Numerous reports document cases of iatrogenic sarcoidosis or sarcoidlike granulomatosis in the setting of biologic therapy with interferon (IFN)-a, tumor necrosis factor (TNF)-a inhibitors, and, most recently, immune checkpoint inhibitors. Anakinra, an interleukin (IL)-1 receptor antagonist (IL-1Ra), has only been reported once in the literature to induce sarcoidlike granulomatosis in a patient with TNF receptoreassociated periodic syndrome. 1 In this report, IL-1Raeinduced sarcoidal granulomas are postulated to be caused by the upregulation of type 1 IFN and IL-1 cytokine pathway inflammation.
CASE REPORT
A 48-year-old woman with long-standing pathology-confirmed chronic hidradenitis suppurativa (Hurley stage III), sequentially treated with doxycycline, minocycline, clindamycin-rifampin, cyclosporine, and adalimumab, was taking anakinra monotherapy (100 mg/d subcutaneous injection for 9 months followed by 200 mg/d subcutaneous T helper cell type 1 TNF:
tumor necrosis factor injection for 15 months) when she presented with acute onset of a tender, warm, erythematous, plaquelike eruption on the bilateral buttocks (Fig 1) . The patient was admitted to the hospital for a presumed soft tissue infection from chronic immunosuppression. Blood cultures and IFN-g release assay were negative. A skin biopsy found an exuberant granulomatous process comprised predominantly of naked noncaseating granulomas throughout the dermis (Fig 2) . Fite, acid-fast bacilli, fungal, and bacterial stains were negative. A workup for sarcoidosis was initiated. The patient's complete blood count with differential, basic metabolic panel, serum Ca 21 , and thyroid function tests were all within normal limits. Electrocardiogram, transthoracic echocardiogram, chest radiography, and dilated fundal examinations found nothing consistent with sarcoidosis. The patient deferred colonoscopy, as she had no signs or symptoms of inflammatory bowel disease. Anakinra was discontinued, as the treatment was only moderately successful and because of new literature on antieIL-17 effectiveness in hidradenitis suppurativa. The buttock eruption improved over 4 months with no therapy until secukinumab was approved. The eruption showed no residual activity at the last clinical evaluation performed 11 months after the cessation of anakinra. 
DISCUSSION
Granulomatous drug eruptions consist of druginduced reactive granulomatous disease, accelerated rheumatoid nodulosis, drug-induced granuloma annulare, and drug-induced sarcoidosis.
2 Drug-induced sarcoidosis (Table I ) may cause polymorphic skin lesions and possible systemic involvement weeks to months after drug initiation. 1, 20 Diagnosis of isolated single-organ sarcoidosis or sarcoidlike granulomatosis depends on the evolving definition of sarcoidosis and acknowledgement of a single organ variant. 20 The most frequently cited cause of drug-induced sarcoidosis is IFN-a, a type I IFN thought to induce sarcoid granuloma formation via induction of a predominant T helper cell type 1 (Th1) cytokine response.
2 Granuloma formation is predominantly Th1, with IFN and TNF critical cytokines; however, TNF inhibitoreinduced granulomas are more confusing. The formation of anti-TNF drug-induced psoriasis and sarcoid granulomas, theoretically results from imbalances in TNF receptor 2emediated activation of regulatory T cells and eventual Th1 T cells or enhancement of local IFN-g. 4, 5 Immune checkpoint inhibitors can induce sarcoidosis by modifying cytotoxic, Th1/17 and regulatory T-cell ratios. 10, 21 A similar mechanism may underlie the induction of sarcoidosis in the setting of anakinra, a recombinant IL-1 receptor antagonist that competitively blocks IL-1. Studies support a strong counter-regulation effect between IL-1 and type I IFN cytokine pathway, with elevated levels of IL-1b potently antagonizing type I IFN. 22 Thus, anakinra therapy may mitigate regulatory mechanisms on type I IFN leading to a paradoxical increase in granulomatous inflammation and a predominant Th1 cytokine response.
In this case, resolution of cutaneous symptoms after cessation of anakinra therapy suggests anakinra-induced sarcoidosis. As such, this report supports expansion of the classes of drugs associated with drug-induced sarcoidosis to include IL-1 receptor antagonists. The diagnosis of drug-induced sarcoidosis is complicated both by the variable time lapse between drug initiation and lesion presentation and the heterogeneous clinical presentation of the disease. 19 Thus, it is important to maintain a high index of suspicion for drug-induced sarcoidosis in patients on biologic therapies including anakinra.
